454 related articles for article (PubMed ID: 22649106)
1. GATA2 zinc finger 1 mutations associated with biallelic CEBPA mutations define a unique genetic entity of acute myeloid leukemia.
Greif PA; Dufour A; Konstandin NP; Ksienzyk B; Zellmeier E; Tizazu B; Sturm J; Benthaus T; Herold T; Yaghmaie M; Dörge P; Hopfner KP; Hauser A; Graf A; Krebs S; Blum H; Kakadia PM; Schneider S; Hoster E; Schneider F; Stanulla M; Braess J; Sauerland MC; Berdel WE; Büchner T; Woermann BJ; Hiddemann W; Spiekermann K; Bohlander SK
Blood; 2012 Jul; 120(2):395-403. PubMed ID: 22649106
[TBL] [Abstract][Full Text] [Related]
2. Genetic heterogeneity of cytogenetically normal AML with mutations of
Konstandin NP; Pastore F; Herold T; Dufour A; Rothenberg-Thurley M; Hinrichsen T; Ksienzyk B; Tschuri S; Schneider S; Hoster E; Berdel WE; Woermann BJ; Sauerland MC; Braess J; Bohlander SK; Klein HG; Hiddemann W; Metzeler KH; Spiekermann K
Blood Adv; 2018 Oct; 2(20):2724-2731. PubMed ID: 30337300
[TBL] [Abstract][Full Text] [Related]
3. GATA2 zinc finger 1 mutations are associated with distinct clinico-biological features and outcomes different from GATA2 zinc finger 2 mutations in adult acute myeloid leukemia.
Tien FM; Hou HA; Tsai CH; Tang JL; Chiu YC; Chen CY; Kuo YY; Tseng MH; Peng YL; Liu MC; Liu CW; Liao XW; Lin LI; Lin CT; Wu SJ; Ko BS; Hsu SC; Huang SY; Yao M; Chou WC; Tien HF
Blood Cancer J; 2018 Aug; 8(9):87. PubMed ID: 30190467
[TBL] [Abstract][Full Text] [Related]
4. Acute myeloid leukemia with biallelic CEBPA gene mutations and normal karyotype represents a distinct genetic entity associated with a favorable clinical outcome.
Dufour A; Schneider F; Metzeler KH; Hoster E; Schneider S; Zellmeier E; Benthaus T; Sauerland MC; Berdel WE; Büchner T; Wörmann B; Braess J; Hiddemann W; Bohlander SK; Spiekermann K
J Clin Oncol; 2010 Feb; 28(4):570-7. PubMed ID: 20038735
[TBL] [Abstract][Full Text] [Related]
5. GATA2 mutations in patients with acute myeloid leukemia-paired samples analyses show that the mutation is unstable during disease evolution.
Hou HA; Lin YC; Kuo YY; Chou WC; Lin CC; Liu CY; Chen CY; Lin LI; Tseng MH; Huang CF; Chiang YC; Liu MC; Liu CW; Tang JL; Yao M; Huang SY; Ko BS; Hsu SC; Wu SJ; Tsay W; Chen YC; Tien HF
Ann Hematol; 2015 Feb; 94(2):211-21. PubMed ID: 25241285
[TBL] [Abstract][Full Text] [Related]
6. Laboratory evaluation and prognostication among adults and children with CEBPA-mutant acute myeloid leukemia.
Mendoza H; Podoltsev NA; Siddon AJ
Int J Lab Hematol; 2021 Jul; 43 Suppl 1():86-95. PubMed ID: 34288448
[TBL] [Abstract][Full Text] [Related]
7. [Gene Profile and Clinical Significance of Concomitant Mutations in CN-AML Patients with
Zhu J; Kang YF; Gao Y; Wang HW; Hao ZH; Wang HW
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Apr; 32(2):335-341. PubMed ID: 38660833
[TBL] [Abstract][Full Text] [Related]
8. GATA2 mutations in sporadic and familial acute myeloid leukaemia patients with CEBPA mutations.
Green CL; Tawana K; Hills RK; Bödör C; Fitzgibbon J; Inglott S; Ancliff P; Burnett AK; Linch DC; Gale RE
Br J Haematol; 2013 Jun; 161(5):701-705. PubMed ID: 23560626
[TBL] [Abstract][Full Text] [Related]
9. Exome sequencing identifies highly recurrent somatic GATA2 and CEBPA mutations in acute erythroid leukemia.
Ping N; Sun A; Song Y; Wang Q; Yin J; Cheng W; Xu Y; Wen L; Yao H; Ma L; Qiu H; Ruan C; Wu D; Chen S
Leukemia; 2017 Jan; 31(1):195-202. PubMed ID: 27389056
[TBL] [Abstract][Full Text] [Related]
10. TET2 lesions enhance the aggressiveness of CEBPA-mutant acute myeloid leukemia by rebalancing GATA2 expression.
Heyes E; Wilhelmson AS; Wenzel A; Manhart G; Eder T; Schuster MB; Rzepa E; Pundhir S; D'Altri T; Frank AK; Gentil C; Woessmann J; Schoof EM; Meggendorfer M; Schwaller J; Haferlach T; Grebien F; Porse BT
Nat Commun; 2023 Oct; 14(1):6185. PubMed ID: 37794021
[TBL] [Abstract][Full Text] [Related]
11. Monoallelic CEBPA mutations in normal karyotype acute myeloid leukemia: independent favorable prognostic factor within NPM1 mutated patients.
Dufour A; Schneider F; Hoster E; Benthaus T; Ksienzyk B; Schneider S; Kakadia PM; Sauerland MC; Berdel WE; Büchner T; Wörmann B; Braess J; Subklewe M; Hiddemann W; Bohlander SK; Spiekermann K;
Ann Hematol; 2012 Jul; 91(7):1051-63. PubMed ID: 22362118
[TBL] [Abstract][Full Text] [Related]
12. Allele-specific expression of GATA2 due to epigenetic dysregulation in CEBPA double-mutant AML.
Mulet-Lazaro R; van Herk S; Erpelinck C; Bindels E; Sanders MA; Vermeulen C; Renkens I; Valk P; Melnick AM; de Ridder J; Rehli M; Gebhard C; Delwel R; Wouters BJ
Blood; 2021 Jul; 138(2):160-177. PubMed ID: 33831168
[TBL] [Abstract][Full Text] [Related]
13. GATA2 mutations are frequent in intermediate-risk karyotype AML with biallelic CEBPA mutations and are associated with favorable prognosis.
Fasan A; Eder C; Haferlach C; Grossmann V; Kohlmann A; Dicker F; Kern W; Haferlach T; Schnittger S
Leukemia; 2013 Feb; 27(2):482-5. PubMed ID: 22814295
[No Abstract] [Full Text] [Related]
14. Favorable prognosis of biallelic CEBPA gene mutations in acute myeloid leukemia patients: a meta-analysis.
Li HY; Deng DH; Huang Y; Ye FH; Huang LL; Xiao Q; Zhang B; Ye BB; Lai YR; Mo ZN; Liu ZF
Eur J Haematol; 2015 May; 94(5):439-48. PubMed ID: 25227715
[TBL] [Abstract][Full Text] [Related]
15. CEBPA double-mutated acute myeloid leukaemia harbours concomitant molecular mutations in 76·8% of cases with TET2 and GATA2 alterations impacting prognosis.
Grossmann V; Haferlach C; Nadarajah N; Fasan A; Weissmann S; Roller A; Eder C; Stopp E; Kern W; Haferlach T; Kohlmann A; Schnittger S
Br J Haematol; 2013 Jun; 161(5):649-658. PubMed ID: 23521373
[TBL] [Abstract][Full Text] [Related]
16. What Is Abnormal in Normal Karyotype Acute Myeloid Leukemia in Children? Analysis of the Mutational Landscape and Prognosis of the TARGET-AML Cohort.
Herlin MK; Yones SA; Kjeldsen E; Holmfeldt L; Hasle H
Genes (Basel); 2021 May; 12(6):. PubMed ID: 34064268
[TBL] [Abstract][Full Text] [Related]
17. CEBPA gene mutations in Egyptian acute myeloid leukemia patients: impact on prognosis.
Awad MM; Aladle DA; Abousamra NK; Elghannam DM; Fawzy IM
Hematology; 2013 Mar; 18(2):61-8. PubMed ID: 22990006
[TBL] [Abstract][Full Text] [Related]
18. Mutations of the GATA2 and CEBPA genes in paediatric acute myeloid leukaemia.
Shiba N; Funato M; Ohki K; Park MJ; Mizushima Y; Adachi S; Kobayashi M; Kinoshita A; Sotomatsu M; Arakawa H; Tawa A; Horibe K; Tsukimoto I; Hayashi Y
Br J Haematol; 2014 Jan; 164(1):142-5. PubMed ID: 24033149
[No Abstract] [Full Text] [Related]
19. Molecular evaluation of CEBPA gene mutation in normal karyotype acute myeloid leukemia: a comparison of two methods and report of novel CEBPA mutations from Indian acute myeloid leukemia patients.
Ahmad F; Rajput S; Mandava S; Das BR
Genet Test Mol Biomarkers; 2012 Jul; 16(7):707-15. PubMed ID: 22731647
[TBL] [Abstract][Full Text] [Related]
20. Deficient CEBPA DNA binding function in normal karyotype AML patients is associated with favorable prognosis.
Fos J; Pabst T; Petkovic V; Ratschiller D; Mueller BU
Blood; 2011 May; 117(18):4881-4. PubMed ID: 21389317
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
